MHB088C not checked

Qilu Pharmaceutical · QLC5508

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
10 active
11 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle”In the company’s words, NCT06954246 on ClinicalTrials.gov
Tested for
Small Cell Lung Cancer Extensive Stage, Esophageal Squamous Cell Carcinoma (ESCC), Prostate Cancer, Extensive-stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Advanced/Metastatic Solid Tumors, Advanced Solid Tumor, Advanced Prostate Cancer and 2 more
Main trialPhase 3
“This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).”In the company’s words, NCT06954246 on ClinicalTrials.gov
Other names
QLC5508

Other drugs for Small Cell Lung Cancer Extensive Stage

All 118 drugs for Small Cell Lung Cancer Extensive Stage

Coming up8

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting May 2027 A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3Recruiting 5 Jun 2028 QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3Not yet recruiting 20 Jun 2028 QLC5508 in Participants With Metastatic Prostate Cancer
Phase 3Recruiting 15 Mar 2029 A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
Phase 3Not yet recruiting 26 Mar 2029 QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Phase 1/2Recruiting Jul 2026 Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Phase 1/2Recruiting Oct 2026 A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Phase 1/2Recruiting Dec 2026 A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Phase 1/2Recruiting Aug 2029 A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Phase 1Recruiting 5 Dec 2026 Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
Phase 1/2Unknown 31 Jan 2026 Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MHB088C

Following is part of Solo: you see every change to MHB088C the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in